Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.

被引:12
|
作者
Sana, Talea [1 ]
Qayyum, Shaista [2 ]
Jabeen, Almas [2 ]
Siddiqui, Bina S. [1 ]
Begum, Sabira [1 ]
Siddiqui, Rafat A. [3 ]
Hadda, Taibi B. [4 ]
机构
[1] Univ Karachi, HEJ Res Inst Chem, Int Ctr Chem & Biol Sci, Karachi 75270, Pakistan
[2] Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, Int Ctr Chem & Biol Sci, Karachi 75270, Pakistan
[3] Virginia State Univ, Food Chem & Nutr Sci Res Lab, Petersburg, VA USA
[4] Univ Mohammed Premier, Fac Sci, Lab Chim Materiaux, Oujda 60000, Morocco
关键词
Anti-inflammatory; Anti-lymphoma; Nyctanthesin A; B; -Cells; Non -Hodgkin lymphoma; PHENYLETHANOID GLYCOSIDES; CANCER; ASSAY; PROLIFERATION; GROWTH; LEAVES;
D O I
10.1016/j.jep.2022.115267
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Nyctanthes arbor-tristis Linn. is native to Indo-Pak sub-continent and has high medicinal values in Ayureda. This plant has been used traditionally for the treatment of sciatica, rheumatism, chronic fever, diabetes, snakebite, dysentery, cachexia and cancer. Studies have shown many pharmacological properties such as anti-cancer efficacy against Dalton's ascetic lymphoma, cytotoxicity against T-cell leukemia, anti-inflammatory, anti-diabetic and anti-oxidant effects. Aim of the study:Aim of the study was to explore the anti-inflammatory and anti-proliferative potential of N. arbor-tristis.Material and methods: Ethanol extract of fresh and uncrushed aerial parts of N. arbor-tristis was used in the present study. A new compound nyctanthesin A was isolated following a bioactivity-guided fractionation and chro-matographic separations. Its chemical structure was elucidated through spectral studies including 1D, 2D-NMR experiments and HREIMS. The intracellular reactive oxygen species (ROS) and nitric oxide (NO) generation from phagocytes were detected by chemiluminescence technique and Griess method, respectively. TNF-alpha and TGF-fi production was quantified by ELISA. Anti-lymphoma and cytotoxic activities were assessed by alamar blue and MTT assays, respectively. The transcription and protein expression level of Bcl-2, COX-2, p38 MAPK, PDL-1, NF-Kappa B, c-Myc and PNF-Kappa B was performed by qRT-PCR and protein blot assays, respectively.Results: Petroleum ether insoluble fraction of the ethanol extract of fresh and uncrushed aerial parts of N. arbor-tristis revealed anti-inflammatory potential by inhibiting ROS. A previously undescribed compound nyctanthesin A was isolated from this fraction and characterized by UV, IR, NMR and HREIMS. It showed significant anti-inflammatory property by inhibiting ROS, NO and TNF-alpha production. The strong anti-proliferative effects on B-cell lymphoma cells, DOHH2 and Raji, revealed its anti-lymphoma potential along with non-toxic profile against BJ and NIH-3T3 fibroblast cells of normal origin. The qRT-PCR results showed marked inhibition of Bcl-2, COX-2, p38 MAPK, PDL-1, c-Myc, NF-Kappa B, and PNF-Kappa B at transcription level in DOHH2 cells with comparatively lesser but significant effects in Raji cells, where the expression of Bcl-2 gene was not affected. The protein expression of PNF-Kappa B in DOHH2 cells was inhibited by 66% (P < 0.05) and COX-2 in both cell lines was inhibited by 50% (P < 0.05) at 60 mu g/mL. A moderate non-significant inhibition of TGF-fi (~20%) was observed in both cell lines at 100 mu g/mL Conclusions: Scientific evidences reported here validate the anti-inflammatory and anti-cancer potential of the plant.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
    Anderson, DR
    GrilloLopez, A
    Varns, C
    Chambers, KS
    Hanna, N
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) : 705 - 708
  • [32] STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMA (NHL)
    Yu, A.
    Abrahams, C.
    Embry, M.
    Li, X.
    DeAlmeida, V.
    Lee, J.
    Matheny, S.
    Kline, T.
    Yam, A.
    Stafford, R.
    Hallam, T.
    Lupher, M.
    Molina, A.
    HAEMATOLOGICA, 2017, 102 : 564 - 564
  • [33] Rituximab (anti-CD20 monoclonal antibody) immunotherapy in patients with B-cell non-Hodgkin's lymphoma:: highly effective treatment of residual disease
    Papajík, T
    Szotkowski, T
    Raida, L
    Hubáek, J
    Faber, E
    Hlusí, A
    Vondráková, J
    Pikalová, Z
    Jedliková, K
    Jarosová, M
    Indrák, K
    LEUKEMIA, 2001, 15 (03) : 510 - 510
  • [34] Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents
    Xue, Kai
    Gu, Juan
    Mavis, Cory
    Hernandez, Francisco
    Czuczman, Myron S.
    Guo, Ye
    BLOOD, 2014, 124 (21)
  • [35] Molecular disease monitoring in patients with relapsed/refractory B-cell non-Hodgkin lymphoma receiving anti-CD19 CAR T-cell therapy.
    Colton, Meryl D.
    Purev, Enkhtsetseg
    Haverkos, Bradley
    Bair, Steven Michael
    Jasem, Jagar
    Schliekelman, Mark Jason
    Kamdar, Manali K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
    Christian, Beth A.
    Poi, Ming
    Jones, Jeffrey A.
    Porcu, Pierluigi
    Maddocks, Kami
    Flynn, Joseph M.
    Benson, Don M.
    Phelps, Mitch A.
    Wei, Lai
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 701 - 710
  • [37] Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes
    Bannerji, Rajat
    Arnason, Jon E.
    Advani, Ranjana
    Brown, Jennifer R.
    Allan, John N.
    Ansell, Stephen M.
    Barnes, Jeffrey
    O'Brien, Susan M.
    Chavez, Julio C.
    Duell, Johannes
    Lowy, Israel
    Charnas, Robert
    Sternberg, David
    Ambati, Srikanth
    Adriaens, Lieve
    Ufkin, Melanie
    Yan, Xiaoyu
    Li, Jingjin
    Navarro, Mark
    Gasparini, Peter
    Jankovic, Vladimir
    Fiaschi, Nathalie
    Zhang, Wen
    Hamon, Sara
    Thurston, Gavin
    Topp, Max S.
    BLOOD, 2018, 132
  • [38] Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma
    Misuzu Fujita
    Shigeru Kusumoto
    Itsuko Ishii
    Tadashi Iwata
    Takehiko Fujisawa
    Masaya Sugiyama
    Akira Hata
    Masashi Mizokami
    Scientific Reports, 12
  • [39] A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity
    Jiang, Linlin
    Yang, Ming
    Zhang, Xiaoyun
    Bao, Shiqi
    Ma, Li
    Fan, Dongmei
    Zhou, Yuan
    Xiong, Dongsheng
    Zhen, Yongsu
    JOURNAL OF DRUG TARGETING, 2016, 24 (01) : 47 - 57
  • [40] Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma
    Fujita, Misuzu
    Kusumoto, Shigeru
    Ishii, Itsuko
    Iwata, Tadashi
    Fujisawa, Takehiko
    Sugiyama, Masaya
    Hata, Akira
    Mizokami, Masashi
    SCIENTIFIC REPORTS, 2022, 12 (01)